By inspecting their oncoprint (Fig. 3f), 27/59 tumours harboured mutations in either SOX9 or MYC and were wild-type in either BRAF, KRAS or NRAS, hinting towards an alternative cetuximab resistance mechanism. Here, KRAS is linked to neoplasm.